免疫监测显示托珠单抗治疗的巨细胞动脉炎存在延长的亚临床疾病活动
本研究在首个评估托珠单抗治疗巨细胞动脉炎(GCA)的随机双盲安慰剂对照试验中,前瞻性检测血清免疫炎症标志物,并与年龄性别匹配的健康志愿者比较。结果显示,托珠单抗联合糖皮质激素治疗早期虽达临床缓解,MMP-3、pentraxin-3和sTNFR2显著升高而ICAM-1和CD163显著降低;研究末期托珠单抗单药治疗使免疫炎症分子几乎完全正常化。结论提示GCA存在亚临床疾病活动,托珠单抗治疗至少52周才能重置广泛的免疫炎症通路。
要点
- 托珠单抗联合糖皮质激素治疗早期临床缓解时,MMP-3、pentraxin-3和sTNFR2仍显著升高,ICAM-1和CD163显著降低。
- 研究末期托珠单抗单药治疗使免疫炎症分子几乎完全正常化。
- MMP-3水平与磁共振信号强度呈弱关联,无生物标志物可预测研究结束后6个月内的复发。
核心结论
- GCA存在亚临床疾病活动,治疗早期更明显,研究末期几乎消失。
- 托珠单抗治疗至少52周才能重置广泛的免疫炎症通路。
研究设计与样本
- 前瞻性收集首个评估托珠单抗治疗GCA的随机双盲安慰剂对照试验的血清。
- 同时检测年龄和性别匹配的健康志愿者的血清作为对照。
- 采用luminex技术定量免疫炎症标志物。
主要发现
- 在托珠单抗联合糖皮质激素治疗下临床完全缓解的时间点,仅MMP-3、pentraxin-3和sTNFR2显著升高,ICAM-1和CD163显著降低。
- 研究末期托珠单抗单药治疗使免疫炎症分子几乎完全正常化(以健康对照定义)。
- MMP-3水平与磁共振信号强度呈弱关联。
- 无生物标志物预测研究结束后6个月内发生的复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tocilizumab is effective in inducing and maintaining remission of GCA. Despite clinical and serological control of disease, magnetic resonance angiography may show persistence of inflammatory signals of unknown significance in arterial walls. Thus, there is an unmet need for tools to detect subclinical disease activity. METHODS: Immune-inflammatory markers were measured in prospectively collected sera of the first randomized, double-blind, placebo-controlled trial investigating the use of tocilizumab in GCA. As a comparison, immune-inflammatory markers were also measured in sera from age- and sex-matched healthy volunteers. The biomarkers were quantified using luminex technology. RESULTS: Of all the parameters determined, only MMP-3, pentraxin-3 and sTNFR2 were significantly elevated, while ICAM-1 and CD163 were significantly decreased during the early stages of the study, at time points of full clinical remission under treatment with tocilizumab plus glucocorticoids. In contrast, tocilizumab monotherapy towards the end of the study resulted in an almost complete normalization of immune-inflammatory molecules, as defined by the healthy controls. MMP-3 levels showed a weak association with magnetic resonance signal intensity; none of the biomarkers predicted relapse occurring within 6 months after study end. CONCLUSION: The data documented a subclinical disease activity in GCA that was more pronounced during the early stages of treatment and almost disappeared towards the study end. They indicated that tocilizumab treatment of at least 52 weeks is necessary in order to reset a broad range of immune-inflammatory pathways. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT01450137.
引用
- Gloor AD, Yerly D, Adler S, et al. Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis. Rheumatology (Oxford). 2018. PMID: 29961816. doi:10.1093/rheumatology/key158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。